Effectiveness of the Personalized Responses & Integrated Systems for Metabolism (PRISM) on Improving Insulin Resistance Among Adults With Metabolic Syndrome: A Pilot Study (PRISM-I)
NCT07710274 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2026-07-17
Summary
The primary objective of the Personalized Responses \& Integrated Systems for Metabolism (PRISM-I) pilot study is to assess the feasibility of conducting a definitive randomized controlled trial evaluating precision lifestyle interventions for improving insulin resistance in adults with metabolic syndrome.
Conditions
- Metabolic Syndrome (MetS)
Interventions
- BEHAVIORAL
-
Time-restricted eating
Following a 2-week baseline assessment, participants will begin a time-restricted eating (TRE) intervention by consuming all meals within a self-selected 8-hour eating window and fasting for the remaining 16 hours each day. They will measure blood ketone levels daily before breaking their fast using a glucometer. At Week 6, participants will be randomly assigned an additional lifestyle intervention (physical activity, low glycemic load diet, or sleep hygiene).
- BEHAVIORAL
-
Physical Activity
Following a 2-week baseline assessment, participants will begin a physical activity intervention. They will be instructed to complete home-based resistance training three times per week and aerobic interval training twice per week using a guided exercise programme. Exercise sessions will be performed independently without direct supervision. Participants will also be encouraged to aim for at least 8,000 steps daily, take a 15-minute walk after lunch and dinner where feasible, and break up prolonged sitting every 30-60 minutes with light movement or standing. At Week 6, participants will be randomly assigned an additional lifestyle intervention (time-restricted eating, low-glycemic load diet, or sleep hygiene).
- BEHAVIORAL
-
Low Glycemic Load diet
Following a 2-week baseline assessment, participants will begin a low-glycaemic load (GL) diet intervention. They will be instructed to replace high-GL foods with lower-GL alternatives, reduce their intake of refined carbohydrates, sugary foods and beverages, and ultra-processed foods, and follow healthy meal composition and meal sequencing principles. At Week 6, participants will be randomly assigned an additional lifestyle intervention (time-restricted eating, physical activity, or sleep hygiene).
- BEHAVIORAL
-
Sleep hygiene
Following a 2-week baseline assessment, participants will begin a sleep hygiene intervention. They will be instructed to adopt healthy sleep habits, including maintaining a regular sleep schedule with adequate sleep duration, practicing good bedtime routines, and optimizing the sleep environment to improve sleep quality. At Week 6, participants will be randomly assigned an additional lifestyle intervention (time-restricted eating, physical activity, or a low-glycemic load diet).
Sponsors & Collaborators
-
National University Health System, Singapore
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 21 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-07-31
- Primary Completion
- 2027-07-31
- Completion
- 2027-07-31
Countries
- Singapore
Study Locations
More Related Trials
-
Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance
NCT00085982 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Intermittent Fasting for the Treatment of Type 2 Diabetes Mellitus
NCT05860413 ·Status: COMPLETED ·Phase: NA
-
Protection Against Insulin Resistance in Obesity
NCT02717832 ·Status: COMPLETED ·Phase: NA
-
Effectiveness of Glucose Control, β Cell Function in Response to Short-term Insulin Pump Therapy in Type 2 Diabetes
NCT03509324 ·Status: COMPLETED ·Phase: PHASE4
-
Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease
NCT07566299 ·Status: COMPLETED
-
Effects of Standing on Glycemia in Prediabetic Adults
NCT01884792 ·Status: COMPLETED ·Phase: NA
-
Glucose Response in Persons with Type 2 Diabetes
NCT04914559 ·Status: COMPLETED ·Phase: NA
-
PGC-1 & MUSCLE MITOCHONDRIAL DYSFUNCTION IN DIABETES: AIMS 1-4
NCT03323788 ·Status: UNKNOWN
-
Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus
NCT01954147 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
NCT00212290 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain
NCT02745470 ·Status: COMPLETED ·Phase: NA
-
Investigating the Role of the Polyol Pathway in the Central Nervous System
NCT02272556 ·Status: COMPLETED ·Phase: NA
-
Interplay of Central and Peripheral Vascular Effects of Insulin in Obesity
NCT07653464 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
MOLECULAR REGULATION OF MUSCLE GLUCOSE METABOLISM (AIMS 2A, 2B, 3)
NCT03323827 ·Status: UNKNOWN
-
Fetuin-A Phosphorylation Status in Insulin Resistance and Metabolic Syndrome
NCT03478046 ·Status: COMPLETED ·Phase: NA
-
Effects of Short-term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes Patients
NCT01588743 ·Status: UNKNOWN ·Phase: NA
-
Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes
NCT06825182 ·Status: RECRUITING ·Phase: PHASE3
-
Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance
NCT01240252 ·Status: COMPLETED ·Phase: PHASE1
-
The Exploreration of the Management for the Positive IAA in Patients With Type 2 Diabetes After Premix Insulin Therapy
NCT05578352 ·Status: UNKNOWN ·Phase: NA
-
Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
NCT05553093 ·Status: RECRUITING ·Phase: PHASE4
-
Effects of Structured Simplified Short-term Intensive Insulin Therapy on Long-term Glycemic Remission
NCT03972982 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients
NCT00437918 ·Status: COMPLETED ·Phase: PHASE4
-
Insulin Therapy in Type 2 Diabetic Patients: Real-life Study on Effectiveness and Satisfaction
NCT06117449 ·Status: NOT_YET_RECRUITING
-
Short-term Effect of Intensive Insulin Therapy on Incretin Secretion
NCT00776243 ·Status: COMPLETED
-
Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome
NCT02337933 ·Status: COMPLETED ·Phase: PHASE2